CheckMate 76K
Melanoma · Medical · Adjuvant stage IIB/C
Population and treatment
790 patients with completely resected stage IIB/C melanoma. Nivolumab 480 mg IV every 4 weeks for 12 months versus placebo.
Reported outcomes
12-month recurrence-free survival 89.0% versus 79.4%; HR 0.42 (95% CI 0.30–0.59; P<0.0001). DMFS HR 0.47 (95% CI 0.30–0.72).
Absolute effect
12-month RFS difference 9.6 percentage points; approximate NNT 11 based on rounded fixed-time rates.
Harms and limitations
Treatment-related grade 3–4 adverse events 10.3% versus 2.3%; one treatment-related death with nivolumab. Initial analysis did not establish OS benefit. Verify current guideline and follow-up context.